BETALOC

This brand name is authorized in Nigeria. It is also authorized in Australia, Croatia, Cyprus, Ecuador, Estonia, Hong Kong SAR China, Ireland, Lithuania, Malta, New Zealand, Poland, Romania, UK.

Active ingredients

The drug BETALOC contains one active pharmaceutical ingredient (API):

1	Metoprolol UNII W5S57Y3A5L - METOPROLOL TARTRATE
	Metoprolol is a cardioselective beta-adrenergic blocking agent. It has a relatively greater blocking effect on beta1-receptors (ie those mediating adrenergic stimulation of heart rate and contractility and release of free fatty acids from fat stores) than on beta2-receptors, which are chiefly involved in broncho and vasodilation.
	Read more about Metoprolol

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
04-6204	Tablet	Betaloc ZOK 100 mg Tablets TAB 100 mg 1 x 30's	Prolonged release tablets. White, round with a diameter of 10 mm, bisected, marked A/mS. The score mark is not intended to divide the tablet into two equal doses. It is only intended to facilitate swallowing	03/08/2021
A4-6202	Tablet	Betaloc ZOK 50 Tablets TAB 50 mg 1 x 30's	Prolonged release tablets. White, round with a diameter of 9 mm, bisected, marked A/mO. The score mark is not intended to divide the tablet into two equal doses. It is only intended to facilitate swallowing	30/04/2024
A4-6203	Tablet	Betaloc ZOK 25 Tablets TAB 25 mg 1 x 30's	Prolonged release tablets. White, oval with a size of 5.5 mm x 10.5 mm, bisected, marked A/B	30/04/2024

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BETALOC Solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C07AB02	Metoprolol	C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents → C07AB Beta blocking agents, selective
Discover more medicines within C07AB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1324Q, 1325R
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	27.695-1-03-12, 27.741-1-03-12
EE	Ravimiamet	1012835, 1019719, 1019720, 1029934, 1072066, 1072077, 1083406, 1083417, 1149061, 1149072, 1149106, 1149117, 1832576, 1832598, 1871906
GB	Medicines & Healthcare Products Regulatory Agency	36160
HK	Department of Health Drug Office	19220, 19614, 19885, 30849, 30850, 34975, 49649
HR	Agencija za lijekove i medicinske proizvode	HR-H-148642958, HR-H-495596644, HR-H-965178809
LT	Valstybinė vaistų kontrolės tarnyba	1002098, 1002099, 1003719, 1004945, 1005306, 1005307, 1010461, 1019766, 1027886, 1027887, 1060286, 1060287, 1072191, 1085825, 1087050
MT	Medicines Authority	AA565/35601
NG	Registered Drug Product Database	04-6204, A4-6202, A4-6203
NZ	Medicines and Medical Devices Safety Authority	7035, 7037, 7038, 9518
PL	Rejestru Produktów Leczniczych	100009914, 100077784, 100077821, 100105948, 100254565, 100264931, 100264960, 100277738, 100277856, 100280120, 100296090, 100307988, 100310476, 100313658, 100314089, 100324521, 100325650, 100325667, 100333187, 100334146, 100336033, 100357839, 100358158, 100358170, 100360994, 100373904, 100374967, 100386500, 100387705, 100387734, 100400216, 100400506, 100400535, 100400676, 100400699, 100400995, 100403031, 100403522, 100403829, 100405691, 100405700, 100405975, 100413472, 100427600, 100435516, 100441379, 100444567, 100444886, 100448170, 100451176, 100454270, 100457646, 100462794, 100463582, 100468542
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66031001, W66032001, W66032002, W66032003, W66033001, W66033002, W66033003, W66034001, W66034002, W66034003, W66034004